期刊档案 · PHARMACOLOGY & PHARMACY
Drug Discoveries and Therapeutics
ISSN 1881-7831 · eISSN 1881-784X · International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)
Drug Discoveries and Therapeutics 中科院 医学 4区（2025 年升级版），影响因子 1.3（官网公布），完全开放获取，APC 约 140 美元，2025 年发文 59 篇，ESCI、Scopus 收录。
研究范围
研究范围与定位
Drug Discoveries and Therapeutics 由 International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 COVID-19 Clinical Research Studies、SARS-CoV-2 and COVID-19 Research、Invertebrate Immune Response Mechanisms 等主题的论文，这 3 个主题约占 21.6%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Drug Discoveries & Therapeutics publishes contributions in all fields of pharmaceutical and therapeutic research such as medicinal chemistry, pharmacology, pharmaceutical analysis, pharmaceutics, pharmaceutical administration, and experimental and clinical studies of effects, mechanisms, or uses of various treatments. Studies in drug-related fields such as biology, biochemistry, physiology, microbiology, and immunology are also within the scope of this journal.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：PHARMACOLOGY & PHARMACY
主编 Nobuyoshi AKIMITSU出版商官网
编委会国家分布：中国大陆 7 位（约 26%）；主要国家 日本 11、中国 7、美国 5、中国香港 2、德国 1（共 27 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- COVID-19 Clinical Research StudiesMedicine7.4%
- SARS-CoV-2 and COVID-19 ResearchMedicine7.1%
- Invertebrate Immune Response MechanismsImmunology and Microbiology7.1%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine5.7%
- Insect Utilization and EffectsAgricultural and Biological Sciences5.2%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics4.5%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics4.5%
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics4.5%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
ESCIScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
期刊官网自述收录
Web of SciencePubMedCASDOAJ出版商官网
其他：EBSCO、Journal Citation Reports | Clarivate Analytics、EBSCO Information Services、National Diet Library, Japan、Japan Medical Abstracts Society、JDream III、J-GLOBAL
期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布）
- 1.3出版商官网 ·
- CiteScore 2026-06
- 3.2LetPub ·
- SJR 2026-06
- 0.26LetPub ·
- SNIP 2026-06
- 0LetPub ·
- h-index
- 43OpenAlex ·
- i10-index
- 346OpenAlex ·
- 两年平均被引
- 2.01OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 99.38%LetPub ·
发文规模
- 年文章数
- 50LetPub ·
逐年发文量 OpenAlex 统计 · 累计 878 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 43 | 43 | 4 |
| 2025 | 59 | 59 | 175 |
| 2024 | 58 | 58 | 143 |
| 2023 | 59 | 59 | 284 |
| 2022 | 60 | 60 | 396 |
| 2021 | 58 | 58 | 594 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取OpenAlex
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| 出版商官网 | USD 140 / USD 340 | — | — |
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点2 项，摘自作者指南
- 正文篇幅
- ≤ 5,000 词
- 投稿信（Cover letter）
- 必须提供
接收的文章类型18 种，含篇幅限制
- brief reportof incomplete or preliminary findings. Brief Reports should not exceed 3,000 words in length (excluding references) and should be limited to a正文 ≤ 3,000 词
- brief reportsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- case reportng medications will also be considered. Case Reports should not exceed 3,000 words in length (excluding references). Communications are short,正文 ≤ 3,000 词
- case reportsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- communicationCommunications are short, timely pieces that spotlight new research findings or policy issues of interest to the field of global health and medical practice tha…未说明篇幅
- communicationsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- editorialence oriented for clinical application. Editorials should not exceed 1,000 words in length (excluding references) and should be limited to a正文 ≤ 1,000 词
- editorialsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- letterLetters should present considered opinions in response to articles published in Drug Discoveries & Therapeutics in the last 6 months or issues of general intere…未说明篇幅
- lettersDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- mini reviewgures and/or tables and 100 references. Mini reviews are also accepted, which should not exceed 4,000 words in length (excluding references) and should be limit…正文 ≤ 4,000 词
- newsNews articles should report the latest events in health sciences and medical research from around the world.未说明篇幅
- original articlession, Acknowledgments, and References. Original articles should not exceed 5,000 words in length (excluding references) and should be limited to a正文 ≤ 5,000 词
- original articlesDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- policy forumPolicy Forum articles discuss research and policy issues in areas related to life science such as public health, the medical care system, and social science and…未说明篇幅
- policy forum articlesDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
- reviews within an area of research. Normally, reviews should not exceed 8,000 words in length (excluding references) and should be limited to a正文 ≤ 8,000 词
- reviewsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …未说明篇幅
官网政策摘录出版伦理、同行评审、试验注册 / 报告规范
- 出版伦理
Formal review and approval (or waiver) by an appropriate institutional review board or ethics committee is required for studies involving human participants or animals. 模型摘要
For all manuscripts reporting data from studies involving human participants or animals, formal review and approval, or formal review and waiver, by an appropriate institutional review board or ethics committee is required and should be described in the Methods section.
原文 ↗出版商官网 ·- 同行评审
Peer review is performed; the journal states it will perform an especially prompt review. 模型摘要
Drug Discoveries & Therapeutics will perform an especially prompt review to encourage innovative work. All original research will be subjected to a rigorous standard of peer review and will be edited by experienced copy editors to the highest standards.
原文 ↗出版商官网 ·- 试验注册 / 报告规范
Clinical trial registration in a public trial registry at or before first patient enrollment is a condition of consideration for publication; the trial registration number will be published at the end of the Abstract. 模型摘要
Registration of clinical trials in a public trial registry at or before the time of first patient enrollment is a condition of consideration for publication in Drug Discoveries & Therapeutics, and the trial registration number will be published at the end of the Abstract.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)
- ISSN
- 1881-7831
- 电子版 ISSN
- 1881-784X
- 官方链接
- 期刊主页 ↗OpenAlex
常见问题
关于 Drug Discoveries and Therapeutics 的常见问题
Drug Discoveries and Therapeutics 是中科院几区期刊？
2025 年升级版分区表中，Drug Discoveries and Therapeutics 为医学 4区，小类 药学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Drug Discoveries and Therapeutics 的影响因子是多少？
期刊官网公布的影响因子为 1.3，属期刊自述数据，LetPub 暂无该刊的影响因子记录，CiteScore 为 3.2，h-index 为 43。
Drug Discoveries and Therapeutics 的投稿格式要求是什么？
据期刊作者指南：正文篇幅：≤ 5,000 词；投稿信：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Drug Discoveries and Therapeutics 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 27 位编委中，中国大陆 7 位（约 26%）；人数最多的国家是 日本（11 位）、中国（7 位）、美国（5 位）。统计按编委会页面列出的机构国家计，仅供参考。
Drug Discoveries and Therapeutics 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Drug Discoveries and Therapeutics 被 ESCI、Scopus 收录。期刊官网自述还被 Web of Science、PubMed、CAS、DOAJ 收录，该清单未与各数据库逐一核对。
Drug Discoveries and Therapeutics 是开放获取期刊吗？版面费多少？
Drug Discoveries and Therapeutics 为完全开放获取。APC 约 140 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-25 归档）。最近更新：。